# Metware

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metware

- Industry: Biotechnology
- Headquarters: Wuhan, China
- Website: www.metware.cn
- Total disclosed funding: $15M
- Latest round: Series B (Apr 2, 2024)
- Investors on record: 4

## About

Established in 2015 and based in Wuhan, China, Metware is a biotech company that focuses on the development of innovative metabolomic technology. It has sub-branch offices in Shenzhen, Beijing, Changsha, and America. The company obtained over 50 patents, including 6 invention patents and 16 utility model patents. It has more than 400 employees, nearly 40% of whom are scientific researchers. In April 2024, it closed series B funding led by new investor Hidea Investment.

The company engages in the development of innovative metabolomic technology. Metware's main business includes innovative metabolomic technology service CRO (Contract Research Organization), chronic metabolic disease prognosis kit development, and early tumour screening "liquid biopsy" metabolic kit development. The products can be used in cancer, metabolic disorders, infectious diseases, agriculture and breeding, microbiome, and other fields. The company's products can be used in application scenarios such as scientific research institutes, hospitals, and industrial enterprises.

The company will use series B funding to expand the company's business layout, increase investment in product technology research and development, and promote the upgrading of key projects.

## Funding rounds

- Series B, Apr 2, 2024 — Hidea Investment
- Series A, Sep 24, 2021, $15M — Hong Shan, Billionhome, Rivercity Investment
- Angel, Sep 22, 2017 — Billionhome

## Investors

- Billionhome (https://capitalatlas.ai/funds/billionhome) — Angel, Series A
- Hong Shan — Series A
- Rivercity Investment (https://capitalatlas.ai/funds/rivercity-investment) — Series A
- Hidea Investment (https://capitalatlas.ai/funds/hidea-investment) — Series B